Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
December 19, 2024Pamplona/MadridIn recruitment
IMC-F106C-301 Trial of BMI-F106C plus nivolumab vs. nivolumab in HLA A*02:01-positive participants with previously untreated advanced melanoma.
The main objective of this study is to know whether the study drug (IMC-F106C at two different doses) in combination with the reference treatment (nivolumab) is better than nivolumab alone in keeping tumors from increasing or decreasing in size. -
December 16, 2024PamplonaIn recruitment
CCTL019A2205B Long-term follow-up of patients exposed to lentiviral vector-based CART cell therapy.
This is a long-term follow-up trial sponsored (funded) by the pharmaceutical company Novartis. If you agree to participate in this study, you will be followed for up to 15 years after your last infusion of your CART cells to assess both the safety and risk of late safety problems suspected to be related to the treatment of your CART cells, or certain laboratory parameters, and efficacy including the status of your primary malignancy. -
December 16, 2024Pamplona/MadridIn recruitment
EIK1003-001 Phase I/II clinical trial of the selective PARP1 inhibitor, IMP1734, in participants with advanced solid tumors.
The main objective of this study is to evaluate the extent to which IMP1734 is tolerated, alone and in combination with other anticancer drugs, as a treatment for patients with ovarian, breast, prostate and pancreatic cancer. -
December 11, 2024Pamplona/MadridIn recruitmentEarly phase
CA119-0002 Ensayo Clínico de BMS-986453, linfocitos T con receptor antigénico quimérico (CAR) con diana doble de BCMAxGPRC5D en sujetos con mieloma múltiple en recaída o refractario [SP]
The objective of this study is to assess whether BMS-986453 is safe and effective for treating people whose multiple myeloma (MM) has recurred after previous treatment (relapsed) or who have MM that is not responding to current treatment (refractory). -
December 11, 2024Pamplona/MadridIn recruitment
SPI-BEL-301 Trial of Beleodaq-CHOP or Folotyn-COP with the CHOP dosing regimen in monotherapy in patients with newly diagnosed peripheral T lymphocyte lymphoma.
Part 1 of this study is mainly aimed at finding out what is the best dose of belinostat and pralatrexate together for administration together with another drug combination in Part 2 of the study. The main objective of Part 2 of the study is to evaluate the safety and efficacy of belinostat together with CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], oncovin [vincristine] and prednisone), and the safety and efficacy of pralatrexate together with COP (CHOP without hydroxydaunorubicin [... -
December 11, 2024Pamplona/MadridIn recruitment
ART0380C001 Trial of ART0380 as oral and gemcitabine treatment in patients with advanced or metastatic solid tumor.
The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be administered along with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be administered to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can th... -
December 5, 2024Pamplona/MadridIn recruitment
M24-287 [SP]
The primary objective is to assess the incidence of treatment-emergent laboratory TLS according to Howard's criteria (Appendix D) or hyperkalemia (potassium > 6.0 mmol/L) requiring clinical intervention as assessed by the Independent Review Committee (IRC) in previously untreated CLL subjects who have reached a median level (any lymph node). (CRI) in previously untreated CLL patients with a median extent (any lymph node [LN] of 5 cm). lymph nodes [LN] from 5 cm to < 10 cm OR absolute l... -
December 5, 2024PamplonaIn recruitmentEarly phase
MCLA-158-CL01 MCLA-158 trial in metastatic colorectal cancer and other advanced solid tumors.
This clinical study will evaluate the safety of MCLA-158 in patients with metastatic colorectal cancer and other advanced solid tumors. -
December 5, 2024MadridIn recruitmentEarly phase
MS201924_0002 Tuvusertib combinado con niraparib o lartesertib en participantes con cáncer epitelial de ovario. [SP]
El principal obejtivo es analizar sus muestras, junto con su información personal y las imágenes obtenidas como parte del ensayo principal para estudiar los genes, averiguar cómo se relacionan estos genes y las variaciones genéticas con la manera en que actúa el tratamiento del ensayo o saber más sobre su enfermedad y la respuesta al tratamiento. -
November 27, 2024Pamplona/MadridIn recruitment
D9970C00001 Phase I/IIa clinical trial of AZD3470 in monotherapy and in combination with anticancer agents in patients with advanced or metastatic MTAP-deficient solid tumors.
The objective of the trial is to evaluate the safety and tolerability and determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents in participants with MTAP advanced solid tumors.